A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.

Journal: Journal of Alzheimer's disease : JAD
Published Date: Jan 1, 2020

Abstract

BACKGROUND: Currently, there is no objective, clinically available tool for the accurate diagnosis of Alzheimer's disease (AD). There is a pressing need for a novel, minimally invasive, cost friendly, and easily accessible tool to diagnose AD, assess disease severity, and prognosticate course. Metabolomics is a promising tool for discovery of new, biologically, and clinically relevant biomarkers for AD detection and classification.

Authors

  • Ali Yilmaz
    Department of Obstetrics and Gynecology, Department of Internal Medicine, Oakland University-William Beaumont School of Medicine, Rochester, MI, USA.
  • Ilyas Ustun
    Wayne State University, Civil and Environmental Engineering, Detroit, MI, USA.
  • Zafer Ugur
    Metabolomics Division, Beaumont Research Institute, Royal Oak, MI USA.
  • Sumeyya Akyol
    Metabolomics Division, Beaumont Research Institute, Royal Oak, MI USA.
  • William T Hu
    Department of Neurology, Emory University, Atlanta, GA, USA.
  • Massimo S Fiandaca
    Department of Neurology, University of California Irvine, Irvine, CA, USA.
  • Mark Mapstone
    Department of Neurology, University of California Irvine, Irvine, CA, USA.
  • Howard Federoff
    Department of Neurology, University of California Irvine, Irvine, CA, USA.
  • Michael Maddens
    Department of Obstetrics and Gynecology, Department of Internal Medicine, Oakland University-William Beaumont School of Medicine, Rochester, MI, USA.
  • Stewart F Graham
    Department of Obstetrics and Gynecology, Department of Internal Medicine, Oakland University-William Beaumont School of Medicine, Rochester, MI, USA.

Keywords

External Resources

Popular Topics
Recent Journals